Immunovia AB (IMMNOV) Price & Analysis

Q: What was Immunovia AB’s price range in the past 12 months?

Immunovia AB lowest stock price was kr0.19 and its highest was kr0.81 in the past 12 months.

Q: What is Immunovia AB’s market cap?

Immunovia AB’s market cap is $164.16M.

Q: When is Immunovia AB’s upcoming earnings report date?

Immunovia AB’s upcoming earnings report date is Feb 24, 2026 which is in 82 days.

Q: How were Immunovia AB’s earnings last quarter?

Immunovia AB released its earnings results on Nov 26, 2025. The company reported -kr0.078 earnings per share for the quarter, missing the consensus estimate of -kr0.047 by -kr0.031.

Q: Is Immunovia AB overvalued?

According to Wall Street analysts Immunovia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Q: Does Immunovia AB pay dividends?

Immunovia AB does not currently pay dividends.

Q: What is Immunovia AB’s EPS estimate?

Immunovia AB’s EPS estimate is -0.04.

Q: How many shares outstanding does Immunovia AB have?

Immunovia AB has 639,991,900 shares outstanding.

Q: What happened to Immunovia AB’s price movement after its last earnings report?

Immunovia AB reported an EPS of -kr0.078 in its last earnings report, missing expectations of -kr0.047. Following the earnings report the stock price went up 7.813%.

Q: Which hedge fund is a major shareholder of Immunovia AB?

Currently, no hedge funds are holding shares in SE:IMMNOV

Compare

3 Followers

IMMNOV Stock Chart & Stats

kr0.28

-kr0.02(-4.98%)

At close: Mar 06 4:00 PM EST

kr0.28

-kr0.02(-4.98%)

Day’s Range― - ―

52-Week Rangekr0.19 - kr0.81

Previous CloseN/A

Volume868.16K

Average Volume (3M)5.10M

Market Cap

$164.16M

Enterprise ValueN/A

Total Cash (Recent Filing)$29.27M

Total Debt (Recent Filing)$467.00K

Price to Earnings (P/E)―

Beta-0.67

Next Earnings

Feb 24, 2026

EPS Estimate

-0.04

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.08

Shares Outstanding639,991,900

10 Day Avg. Volume6,199,351

30 Day Avg. Volume5,096,607

Financial Highlights & Ratios

PEG Ratio<0.01

Price to Book (P/B)3.87

Price to Sales (P/S)48.45

P/FCF Ratio-0.47

Enterprise Value/Market Cap0.00

Enterprise Value/Revenue0.00

Enterprise Value/Gross Profit0.00

Enterprise Value/Ebitda0.00

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Immunovia AB News

Immunovia AB Expands Share Count to Bolster Market Position

The latest update is out from Immunovia AB ( ($SE:IMMNOV) ). Immunovia AB has increased its number of...

6d ago

Immunovia AB’s Earnings Call: Progress and Challenges

Immunovia AB (($SE:IMMNOV)) has held its Q3 earnings call. Read on for the main highlights of the call....

6d ago

Immunovia AB Reports Q3 2025 Earnings and Strategic Progress

Immunovia AB ( ($IMMVF) ) has released its Q3 earnings. Here is a breakdown of the information Immunovia...

7d ago

Immunovia Secures Medicare Payment Rate for PancreaSure Test

An announcement from Immunovia AB ( ($SE:IMMNOV) ) is now available. Immunovia has announced that the Centers for...

8d ago

Immunovia AB Reports Successful Launch of PancreaSure Test and Financial Improvements in Q3 2025

Immunovia AB ( ($SE:IMMNOV) ) has shared an announcement. Immunovia AB has reported a successful third quarter in...

8d ago

Immunovia’s PancreaSure Test Validated in Peer-Reviewed Study

Immunovia AB ( ($SE:IMMNOV) ) has provided an update. Immunovia announced the publication of the VERIFI clinical study...

10d ago

Immunovia to Release Q3 2025 Results and Host Webcast

Immunovia AB ( ($SE:IMMNOV) ) has shared an update. Immunovia AB announced it will release its third-quarter 2025...

14d ago

Immunovia AB Strengthens Capital with Directed Share Issue

Immunovia AB ( ($SE:IMMNOV) ) has shared an announcement. Immunovia AB has announced a directed issue of 32,674,998...

1M ago

Immunovia’s PancreaSure Test Validated in Leading Journal

Immunovia AB ( ($SE:IMMNOV) ) has provided an announcement. Immunovia announced the publication of its CLARITI clinical study...

1M ago

Immunovia’s PancreaSure Test Data to be Highlighted at ACG 2025 Meeting

An update from Immunovia AB ( ($SE:IMMNOV) ) is now available. Immunovia announced that its PancreaSure test’s clinical...

1M ago

Onconetix’s Proteomedix licenses manufacturing IP to Immunovia

Onconetix (ONCO) announced that its wholly owned subsidiary, Proteomedix has signed a licensing agreement, with Immunovia (IMMVF), a...

2M ago

ONCO

Immunovia provides further data from VERIFI study of pancreatic cancer test

Immunovia (IMMVF) announced additional results from the VERIFI study of its next-generation pancreatic cancer test. Immunovia’s next-generation test...

8M ago

IMMNOV FAQ

What was Immunovia AB’s price range in the past 12 months?

Immunovia AB lowest stock price was kr0.19 and its highest was kr0.81 in the past 12 months.

What is Immunovia AB’s market cap?

Immunovia AB’s market cap is $164.16M.

When is Immunovia AB’s upcoming earnings report date?

Immunovia AB’s upcoming earnings report date is Feb 24, 2026 which is in 82 days.

How were Immunovia AB’s earnings last quarter?

Immunovia AB released its earnings results on Nov 26, 2025. The company reported -kr0.078 earnings per share for the quarter, missing the consensus estimate of -kr0.047 by -kr0.031.

Is Immunovia AB overvalued?

According to Wall Street analysts Immunovia AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immunovia AB pay dividends?

Immunovia AB does not currently pay dividends.

What is Immunovia AB’s EPS estimate?

Immunovia AB’s EPS estimate is -0.04.

How many shares outstanding does Immunovia AB have?

Immunovia AB has 639,991,900 shares outstanding.

What happened to Immunovia AB’s price movement after its last earnings report?

Immunovia AB reported an EPS of -kr0.078 in its last earnings report, missing expectations of -kr0.047. Following the earnings report the stock price went up 7.813%.

Which hedge fund is a major shareholder of Immunovia AB?

Currently, no hedge funds are holding shares in SE:IMMNOV

Company Description

Immunovia AB

Immunovia AB (publ), a diagnostic company, develops and commercializes blood tests in Sweden and internationally. The company's product includes IMMray PanCan-d, a blood-based test for the early detection of pancreatic cancer. It also develops research projects for lung cancer. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Immunovia AB (IMMNOV) Earnings & Revenues

Historic Earnings Reports

IMMNOV Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reveals significant progress in Immunovia's commercial transition and positive initial market response to PancreaSure, alongside key milestones in reimbursement rate setting. However, uncertainties remain regarding coverage and revenue timelines.View all SE:IMMNOV earnings summaries